Ahn-Gook Pharmaceutical Co., Ltd. Overview
Ahn-Gook Pharmaceutical is a family-controlled, mid-sized Korean prescription-drug maker that has rebuilt itself since 2021 around domestic chronic-disease combination products. It is founder-led in origin, has had a professional CEO since 2022 and reports roughly KRW 307bn of consolidated FY2025 revenue. Its historic franchise is Synatura (시네츄라), an internally developed botanical antitussive/expectorant syrup that peaked with the COVID-19 respiratory cycle. The growth engine has since shifted to cardiovascular and metabolic tablets, chiefly Fevarozet (pitavastatin/ezetimibe). Fevarozet became the company's largest product in 2026 and also anchors a contract-manufacturing (CMO) business that supplies most competing pitavastatin/ezetimibe generics. A consumer health-and-beauty (H&B) channel pushing health functional foods through Daiso, Olive Young and its own online mall now contributes roughly 9% of sales. Management targets KRW 500bn of revenue and a top-10 UBIST prescription ranking by 2030. A long-running criminal rebate case against the controlling shareholder, plus a 2026 GMP-related manufacturing suspension, are the principal governance and operational overhangs. Valuation is deep-value: below book, single-digit P/E, and a high dividend yield.
What the company does
Ahn-Gook researches, manufactures and sells finished-dose pharmaceuticals in South Korea. Most revenue comes from prescription (ETC) drugs dispensed through the national health insurance reimbursement system. Over-the-counter (OTC) drugs, health functional foods (HFF) and contract manufacturing for third-party pharma companies supplement this. Its own descriptions in DART and on its website emphasise respiratory and cardiovascular therapeutics, improved formulations (개량신약, "incrementally modified drugs") and a "total healthcare" ambition. Aggregator profiles derived from company material describe it as protecting public health since 1959 and as releasing improved new drugs built on internal R&D capability (Fundable/LinkedIn description). They also note a strong focus on respiratory and cardiovascular treatments (financialfilings.com company summary).
Revenue model
| Revenue stream | Description | Disclosed weight |
|---|---|---|
| Own-brand prescription products (제품) | Internally developed or registered generics and combinations: Fevarozet, Synatura, Levotension family, lipid combinations | Majority. Butler.works (Q2 2026) therapeutic split: cardiovascular 47%, respiratory 16%, gastrointestinal 10%, other pharmaceuticals 17% |
| In-licensed / merchandise products (상품) | Products licensed from domestic and foreign companies; Widaplik (George Medicines) is the most recent | — |
| Health functional foods & H&B (건강기능식품 등) | Stick-type supplements and related consumer products via Daiso, Olive Young and own mall | ≈9% (Q2 2026 basis, Butler.works) |
| Contract manufacturing (수탁 생산) | Manufactures pitavastatin/ezetimibe combinations for Daewon, Boryung, Dongkwang, Hanlim and others | Not separately disclosed; Dailypharm (Feb 2026) says Ahn-Gook manufactures every pitavastatin/ezetimibe combination on the market except JW's Livalozet |
| Licensing / royalty | No material out-licensing income disclosed | Negligible |
The model is product-led, with no subscription or service income. The pharmaceutical P&L is typical of a Korean generic/combination specialist: modest gross margins, heavy sales and marketing spend through in-house reps and contract sales organisations (CSOs), and low R&D intensity. Management has been reducing CSO exposure in channels with weak prescription verification. In September 2024 the company told CSOs to stop new long-term-care hospital accounts after prescription documentation repeatedly covered less than 80% of shipped volume (Dealsite, 10 Oct 2024).
Value-chain position
Ahn-Gook is vertically integrated from formulation development through finished-dose manufacturing to domestic marketing. It runs its own finished-dose plant in the Hyangnam pharmaceutical complex, Hwaseong. It buys active pharmaceutical ingredients (APIs) from third parties, and no in-house API synthesis is disclosed. In the pitavastatin/ezetimibe sub-segment it is both brand marketer and toll manufacturer for competitors, an unusual position that lets it earn on rivals' volume growth.
Customer types and end-markets
Prescribers and dispensers: clinics (의원) and hospitals, especially internal medicine, family medicine, cardiology, ENT and paediatrics. Reimbursement is via the National Health Insurance Service, under price regulation by HIRA and the Ministry of Health and Welfare.
Pharmaceutical wholesalers: physical distribution to pharmacies and hospitals.
Retail consumers: OTC drugs through pharmacies; HFF through Daiso, Olive Young, the company's own mall and pharmacies.
Pharma companies (B2B): contract manufacturing customers.
Geography: overwhelmingly domestic. Exports exist but are not quantified, and Dealsite reported a declining export trend in 2024.
Independent characterisation
Ahn-Gook is best understood as a domestic chronic-care combination-product franchise layered on a declining seasonal respiratory brand, with an emerging consumer channel. The 2022–2026 growth (consolidated revenue +114% over five years, per Dailypharm, Feb 2026) came from three things. First, the pandemic and endemic respiratory cycle boosted Synatura. Second, a well-timed patent challenge and fast-follower launch in pitavastatin/ezetimibe gave the company the market's leading generic position. Third, cost discipline produced operating leverage that only became visible in 2026 (Q1 2026 operating margin 16.2%). The company is not a novel-drug innovator. Its R&D is formulation-led, and its pipeline bets are pursued mainly through affiliates and financial investments (MustBio, the Mirae Asset new-growth fund) rather than internal first-in-class programmes.
Strategy
Stated corporate strategy
The strategic framework is "AHN-GOOK 2030 NEW VISION," declared in 2020. It has three pillars (Dealsite, 25 Apr 2024):
-
Business diversification through total healthcare.
-
Launch of differentiated improved new drugs (개량신약).
-
Export expansion.
The company presents the 2024 Gwacheon relocation as the platform for achieving the 2030 vision and for becoming a "K-Health" company (Dailypharm, 30 Apr 2024).
CEO Park In-cheol updated the targets in January 2026 (Dailypharm DP interview, 19 Jan 2026). The themes he set out were:
Revenue of KRW 500bn by 2030: and a top-10 ranking by UBIST outpatient prescription value, with healthcare "plus-alpha" businesses as upside.
Two-track R&D: in-house development accelerated after the Gwacheon R&D Center opened, plus external collaboration.
-
Expanded business development (BD), open innovation and pipeline strengthening.
-
Concentration on the cardiovascular and respiratory axes, with collaboration-based investments in bio and medical devices.
-
Explicit planning for drug-price cuts and tighter regulation.
An August 2025 Dealsite article quoted a target of KRW 500bn by 2027. That conflicts with the 2030 horizon in the CEO's January 2026 interview; the CEO's statement is treated as authoritative.
Strategic initiatives (last 24 months)
| Initiative | Date | Description | Status / target | Source |
|---|---|---|---|---|
| Co-CEO structure, sales & marketing reinforcement | Jan 2025 | Owner + professional CEO model | Implemented | Dailypharm |
| R&D and production reorganisation | Feb 2025 | Specialisation of research and production divisions | Implemented | Dailypharm |
| Organisational culture rebuilding & AI-based work innovation | 2,025 | Internal transformation programme | Ongoing | Dailypharm related headline |
| Shareholder return enhancement | Feb–Oct 2025 | DPS doubled; capital reserve converted to retained earnings | Implemented; FY2025 dividend yield ~7% | Medical Times; Dailypharm |
| New-growth venture fund | Oct 2025 | KRW 20bn fund with Mirae Asset Capital (Ahn-Gook 65%) targeting bio and medical devices | Committed to 2029 | Digital Today; Dailypharm |
| Medical-materials entry | 2025 (date not confirmed) | MOU with SOFNT (nanofibre materials, founded 2020); the company's first venture beyond pharma/bio | MOU stage | CB Insights news summary |
| H&B multichannel | 2025–2026 | HFF through Daiso, Olive Young, own mall | Contributing about 9% of revenue | Dailypharm, May 2026 |
| Widaplik in-licensing | Mar 2026 | First-line triple hypertension combination; builds an initial-to-second-line combination ladder | Korean trials and approval pending | Dailypharm; NewDaily |
| Fevarozet low-dose line extension | Apr 2026 | 1/10 mg approval; responds to the low-dose statin trend | Approved | Dailypharm, 22 Apr 2026 |
| Hyangnam capacity expansion | Jul 2026 | KRW 48.48bn plant extension | Completion end-2027 / Aug 2028 | Dailypharm |
| Dedicated liquid-formulation plant | Sep 2026 | Smart-factory oral-liquid plant | Target Oct 2027 | Medical Times |
| EHS certification maintenance | Jun 2026 | ISO 14001 / ISO 45001 surveillance audits passed at all sites | Maintained | Dailypharm |
Medium-term financial targets and guidance
| Target | Value | Horizon | Source |
|---|---|---|---|
| Revenue | KRW 500bn | 2,030 | Dailypharm DP interview, Jan 2026 |
| Industry rank | Top 10 by UBIST outpatient prescriptions | 2,030 | Same |
| Margin / EPS / dividend guidance | — | — | — |
The company does not issue formal quarterly or annual guidance.
Products & Services
Organised by therapeutic class. Ahn-Gook does not publish product-level pricing; Korean reimbursed drug prices are set by HIRA and are not company pricing decisions.
Cardiovascular & metabolic (≈47% of revenue)
| Product | Composition / description | Key specifications | Target patient / prescriber | Launch / latest version | Notes & source |
|---|---|---|---|---|---|
| Fevarozet (페바로젯) | Pitavastatin calcium + ezetimibe fixed-dose combination | Strengths 2/10 mg and 4/10 mg (Aug 2023); 1/10 mg approved Apr 2026. Proprietary small tablet (10 mm × 4.9 mm), about 46% smaller than the reference Livalozet. Phase 3 at 20 Korean sites showed ~57% LDL-C reduction at week 8 with no observed glycaemic-marker changes | Dyslipidaemia; primary care, cardiology | Approved May 2023; launched Aug 2023; low-dose 1/10 mg Apr 2026 | FY2025 sales KRW 29.1bn; monthly sales above KRW 3.4bn in Dec 2025; Dec-vs-Jan 2025 growth 118% vs 34% for Livalozet (Dailypharm, 5 Feb 2026; 22 Apr 2026) |
| Fevarozet CMO supply | Same molecule manufactured for third parties | Partner brands include Tabarozet (Daewon), Elzerozet, Pizet, Starzet and products for Boryung, Dongkwang, Hanlim | B2B | 2023 onward | Ahn-Gook makes all pitavastatin/ezetimibe combos except Livalozet (Dailypharm, Feb 2026) |
| Fevaro (페바로) | Pitavastatin monotherapy | — | Dyslipidaemia | — | Part of lipid franchise (Dailypharm, Oct 2021) |
| Fevaro-F (페바로에프) | Pitavastatin-based combination (second component not confirmed in sources reviewed) | — | Mixed dyslipidaemia | — | One of the "three lipid combinations" (Dailypharm, Feb 2025) |
| Shuvazet (슈바젯) | Rosuvastatin + ezetimibe | 10/5, 10/10, 10/20 mg | Dyslipidaemia | Approved Oct 2016 | 3-month sales suspension Nov 2021–Jan 2022; H1 2021 Rx about KRW 2.4bn (Dailypharm, 22 Oct 2021) |
| Shustar (슈스타) | Rosuvastatin monotherapy | — | Dyslipidaemia | — | Dailypharm, Oct 2021 |
| Lipozet (리포젯) | Statin + ezetimibe combination (statin not confirmed) | — | Dyslipidaemia | — | Dailypharm, Oct 2021 |
| Levotension (레보텐션정) ("Revo Tension" in English listings) | S-amlodipine (single-enantiomer calcium-channel blocker) | Paediatric indication added | Hypertension | paediatric indication added | Listed as flagship by Yahoo Finance/MarketInOut; Dailypharm related-news list |
| Levosartan family (레보살탄 계열) | S-amlodipine + losartan-based combinations | — | Hypertension | — | Cited as a key tablet franchise (NewDaily, 15 May 2026) |
| Indapamide-based antihypertensive combinations | Indapamide fixed-dose combinations | — | Hypertension | 2025–2026 | NewDaily, 15 May 2026 |
| Widaplik (위다플릭) (in-licensed, pre-launch) | Telmisartan + amlodipine + indapamide, low-dose triple combination | 10/1.25/0.625 mg, 20/2.5/1.25 mg, 40/5/2.5 mg. First fixed-dose combination approved by the US FDA for initial (first-line) hypertension treatment; pivotal data published in The Lancet and JACC | Hypertension, first-line | Korean licence 12 Mar 2026; local trials and MFDS approval pending | Exclusive Korean clinical, regulatory and commercial rights from George Medicines (Dailypharm, 12 Mar 2026) |
| Ahngook Vildagliptin 50 mg (안국빌다글립틴정) | Vildagliptin (DPP-4 inhibitor) generic | First-generic priority sales right | Type 2 diabetes | Approved Nov 2019; exclusivity 30 Aug 2021–29 May 2022 | Dailypharm, 12 Dec 2019 |
| Avesmet (에이브스메트정) | DPP-4 inhibitor + metformin combination | — | Type 2 diabetes | 2,022 | Jobplanet company history |
| Ateneel / Ateneel M (에이테넬정 / 에이테넬엠정) | Teneligliptin (DPP-4) ± metformin | — | Type 2 diabetes | 2022 (per company history; month not confirmed) | Jobplanet company history |
Respiratory (≈16% of revenue)
| Product | Description | Key specifications | Target | Launch | Notes & source |
|---|---|---|---|---|---|
| Synatura (시네츄라시럽) | Internally developed botanical (natural-product) antitussive / expectorant syrup | Oral liquid; ivy-leaf and coptis-based botanical formulation (composition per company labelling; not re-verified here) | Acute bronchitis / cough and sputum; ENT, paediatrics, internal medicine | Launch year not re-verified in this review | FY2025 sales KRW 32.2bn (10.5% of revenue). About KRW 35bn in FY2022 (+100% YoY, Dailypharm column). Prescriptions fell in 2025 on the post-pandemic base effect. US licence (Gravity Bio) terminated pre-2019 |
| Other respiratory liquids | Liquid formulations benefiting from rising demand | — | — | — | Management cites expanding liquid-product demand as the rationale for the new liquid plant (Dailypharm, May 2026; Medical Times, Sep 2026) |
Gastrointestinal (≈10% of revenue)
Product-level detail for the digestive franchise is not disclosed in the sources reviewed. CB Insights describes a "digestive agent" as one of the company's recognised products.
Other pharmaceuticals (≈17% of revenue)
| Product | Description | Target | Launch | Source |
|---|---|---|---|---|
| Amiga SR (에이미가서방정) | Mirabegron extended-release generic | Overactive bladder | May 2022 | Jobplanet company history |
| Tobicom-S (토비콤-에스) | Soft capsule eye-health product (historic OTC brand) | Eye fatigue / ophthalmic nutrition | Jan 1995 | Jobplanet; Morningstar profile notes the company is "famous for medicine for ophthalmology" |
| Ophthalmology line extensions | The company announced entry into the ophthalmology business | Ophthalmology | — | Dailypharm related-news list |
| Dry-eye treatment (co-development) | Co-development agreement with Daewoo Pharm | Dry eye disease | — | Jobplanet company history |
| Neurogate (뉴로게이트) | Sales agreement with Salted (솔티드) for a digital/neuro product | — | — | Dailypharm related-news list |
| Vuno AI fundus screening | Supply agreement for Vuno's AI-based fundus examination solution | Clinics | Mar 2022 | Jobplanet company history |
| GenBody COVID-19 rapid antigen kit | Distribution (historic) | — | Feb 2022 | Jobplanet company history |
| Legacy products | Intercal, Unol, Saerogenta cream, Clio syrup, Dacorin capsules, Tiston, Grandpase triple tablets, Silidu soft capsules | Various | 1990s | Jobplanet company history |
Health functional foods & H&B (≈9% of revenue)
| Offering | Description | Channel | Status | Source |
|---|---|---|---|---|
| Stick-type health functional foods | Single-serve stick supplements; demand growth cited as a Q1 2026 driver | Daiso, Olive Young, own online mall, pharmacies | Expanding 2025–2026 | Dailypharm, 14 May 2026 |
| Daiso range | Lower-price, smaller-pack HFF lines; Ahn-Gook was reported in May 2025 to be negotiating entry | Daiso | Entered (2025–2026) | NewDaily, 7 May 2025; Dailypharm, 14 May 2026 |
Contract manufacturing services
The Hyangnam plant provides toll manufacturing of pitavastatin/ezetimibe combinations for multiple Korean companies. The April 2026 low-dose approval is expected to lift both own-brand and contract revenue (Dailypharm, 22 Apr 2026). Contract-manufacturing revenue is not separately disclosed.
Financial Narrative
Basis: consolidated K-IFRS as transcribed by Butler.works from DART business reports unless stated. Units: KRW 100M. Blank = not publicly disclosed in sources reviewed.
Income statement
Margins derived from Butler.works revenue and profit figures. Revenue CAGR FY2021–FY2025 = 17.0% (derived). DPS: KRW 220 was the long-standing level, doubled to KRW 440 for FY2024 (Medical Times, 17 Oct 2025). FY2025 DPS is not confirmed in sources reviewed. Dailypharm (20 Mar 2026) reports that Ahn-Gook ranked first among 70 Korean pharma/bio companies by FY2025 market dividend yield at about 7%, implying a further DPS increase.
Quarterly trajectory (consolidated)
Sources: ETFshopping (DART quarterly filings); Dailypharm and Medical Times for Q1 2026. Q4 2025 values are derived as FY2025 minus 9M 2025. The implied Q4 2025 operating loss of about KRW 6.0bn suggests year-end charges such as inventory, bonus or R&D true-ups; the nature of these charges is not disclosed in sources reviewed.
H1 2026 vs H1 2025 (derived): revenue KRW 190.8bn vs KRW 152.6bn (+25.0%); operating income KRW 24.6bn vs KRW 10.8bn (+128%); net income KRW 21.0bn vs KRW 6.6bn. Trailing-twelve-month to Q2 2026 (derived): revenue ≈ KRW 345.1bn, operating income ≈ KRW 23.5bn, net income ≈ KRW 21.7bn.
Balance sheet
Sources: total assets at 31 Dec 2024 of KRW 302.54bn (Digital Today, citing the 31 Oct 2025 DART equity-acquisition filing); consolidated equity at 31 Dec 2025 of KRW 166.29bn (Dailypharm, 14 Jul 2026, citing the capex filing). MarketInOut (20 Aug 2026) reports debt/equity of 0.46 and interest coverage of 7.56x on a trailing basis. Butler.works' P/B of 0.74 at a KRW 132.5bn market cap implies book equity of about KRW 179bn at the latest reported date (derived).
Cash flow
Cash-flow statements are not transcribed in accessible sources. Known cash events: Daerim-dong HQ sale of KRW 22.0bn in 2024 (Dailypharm); KRW 13.0bn commitment to the Mirae Asset fund (staged to 30 Oct 2029); KRW 48.48bn Hyangnam expansion capex approved 14 Jul 2026, with stated periods to end-2027 (Dailypharm, 14 Jul 2026) and to end-Aug 2028 (Dailypharm, 28 Jul 2026), a discrepancy noted. No buyback authorisation was disclosed between 2022 and August 2025 (Dealsite, 20 Aug 2025: no treasury-share acquisitions or disposals in three years).
Ratios
FY2025 ROE derived as net income ÷ year-end consolidated equity (73 ÷ 1662.9). Trailing aggregator readings (MarketInOut, 20 Aug 2026): ROE 9.78%, ROA 5.26%, ROIC 7.67%, debt/equity 0.46, interest cover 7.56x, EBITDA (TTM) KRW 30.5bn, Piotroski F-score 8/9, Altman Z 2.63. Stockhub (Jul 2026): ROE 5.49%. Differences reflect different trailing windows.
Commentary on trends, inflections and drivers
Revenue. Consolidated revenue more than doubled from the FY2020 trough of KRW 143.4bn to KRW 306.9bn in FY2025, a 17.0% CAGR from FY2021. The growth came in two waves.
FY2021–FY2023 (respiratory wave): Synatura prescriptions surged through the pandemic and endemic flu/cold seasons. Respiratory reached a quarter of sales in H1 2022.
FY2024–FY2026 (cardiometabolic wave): Fevarozet launched in August 2023 and scaled to KRW 29.1bn in FY2025. Combined with Shuvazet and Fevaro-F, lipid combinations reached KRW 37.8bn of FY2024 prescriptions. This offset Synatura's 2025 normalisation. H1 2026 revenue grew 25% YoY, an acceleration from the 13–16% pace of FY2023–FY2025, with H&B as an incremental driver.
Profitability. For most of the period profitability was structurally thin. Operating margins of 2–5% in FY2022–FY2025 reflected a heavy CSO commission burden, rising cost of goods and inventory write-offs. FY2023's margin compression was attributed to a higher cost ratio, disposal of slow-moving inventory and higher sales-agency commissions on growing revenue (Dailypharm, 21 Feb 2024). The inflection came in Q1 2026: a 16.2% operating margin, against 7.7% a year earlier. Management credits sustained cost management and the shift in mix toward self-manufactured Fevarozet (Medical Times, 15 May 2026). NewDaily described Q1 2026 profitability as the best operating margin in about ten years. Q2 2026 eased to 9.4%, which still more than doubled the margin of Q2 2025.
Net income volatility. FY2024 net income of KRW 16.3bn was inflated by the Daerim-dong HQ disposal gain. FY2025's decline to KRW 7.3bn is a base effect, not deterioration (Medical Times, 19 Mar 2026). FY2023 net income of only KRW 1.0bn reflected weak operating profit and non-operating items.
Balance sheet and capital allocation. The HQ sale and the 2026 earnings step-up created headroom to commit almost KRW 50bn to plant expansion. That commitment equals 29% of equity, which is large relative to the company's size. The company has done this while doubling the dividend and expanding distributable reserves. Treasury shares (12.86%) are unused. Leverage appears moderate (aggregator debt/equity 0.46), but gross debt and cash balances are not disclosed in accessible sources. Analysts should obtain them from the DART filings before drawing liquidity conclusions.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Therapeutic Class Details
| Therapeutic class | Main contents | Share of revenue (%), Q2 2026 basis |
|---|---|---|
Cardiovascular agents (순환기용제) | Fevarozet, Fevaro, Shuvazet, Fevaro-F, Levotension, Levosartan family, Widaplik (pre-launch) | 47 |
Other pharmaceuticals (기타의약품) | Diabetes (vildagliptin, teneligliptin combinations), urology, ophthalmology and others | 17 |
Respiratory agents (호흡기용제) | Synatura syrup and other respiratory products | 16 |
Gastrointestinal agents (소화기계용제) | Digestive products (product-level detail not disclosed) | 10 |
Health functional foods etc. (건강기능식품 등) | Stick-type supplements, H&B products | 9 |
Revenue by Segment (KRW) and Revenue by Segment (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Consolidated revenue (KRW 100M) | 1,635 | 2,054 | 2,337 | 2,711 | 3,069 |
Synatura revenue (KRW 100M) | — | — | — | — | 322 |
Fevarozet revenue (KRW 100M) | — | — | — | — | 291 |
Lipid combinations, 3 products, outpatient Rx value (KRW 100M) | — | — | — | 378 | — |
Synatura share of revenue (%) | — | — | — | — | 10.5 |
Group Entities
| Entity | Relationship | Activity | Notes / source |
|---|---|---|---|
Ahngook Bio Diagnostics (안국바이오진단) | Subsidiary | Diagnostics | Co-located at Gwacheon HQ (Dealsite, Jan 2025); reported as loss-making historically (Dealsite, 2021) |
Ahngook Newpharm (안국뉴팜) | Subsidiary | Pharmaceutical sales/marketing | Co-located at HQ; in capital impairment in 2020 (Dealsite, 2021); former CEO is current Ahn-Gook CEO Park In-cheol |
Bix Bio (빅스바이오) | Subsidiary (as of 2021) | Not detailed | — |
Medifer (메디페르) | Subsidiary (as of 2021) | Not detailed | — |
Ahngook Health (안국건강) | Affiliate (29.98% held as of 2021) | Health functional foods (lutein, eye health) | Controlled by Eo Gwang (54.44%); FY2020 revenue KRW 53.8bn, operating profit KRW 4.2bn (Dealsite, 2021) |
MustBio (머스트바이오) | Related investee / affiliate | Immuno-oncology biologics | Founded by former Ahn-Gook VP and R&D head Kim Maeng-seop; co-development deal with Celltrion, 2025 (Dailypharm, 5 Nov 2025) |
Mirae Asset–Ahn-Gook New Growth Investment Partnership No.1 | 65% interest (KRW 13.0bn of KRW 20bn) | Venture fund (bio, medical devices) | Managed by Mirae Asset Capital (Digital Today, 31 Oct 2025) |
Income Statement (KRW) and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW 100M) | 1,635 | 2,054 | 2,337 | 2,711 | 3,069 |
Revenue growth YoY (%) | 14.0 | 25.6 | 13.8 | 16.0 | 13.2 |
Operating income (KRW 100M) | -11 | 97 | 51 | 67 | 98 |
Net income (KRW 100M) | 37 | 69 | 10 | 163 | 73 |
Dividend per share (KRW) | 220 | 220 | 220 | 440 | — |
Margin metric (%)
| Margin metric (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating margin (%) | -0.7 | 4.7 | 2.2 | 2.5 | 3.2 |
Net margin (%) | 2.3 | 3.4 | 0.4 | 6.0 | 2.4 |
Income Statement (KRW) and Margin Analysis (%) (Quarterly)
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 (implied) | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|
Revenue (KRW 100M) | 707 | 758 | 768 | 777 | 766 | 989 | 919 |
Operating income (KRW 100M) | 12 | 59 | 50 | 49 | -60 | 160 | 86 |
Net income (KRW 100M) | -7 | 35 | 31 | 34 | -27 | 124 | 86 |
Operating margin (%) | 1.7 | 7.8 | 6.5 | 6.3 | -7.8 | 16.2 | 9.4 |
Balance Sheet (KRW)
| Metric | FY2024 | FY2025 |
|---|---|---|
Total assets (KRW 100M) | 3,025.4 | — |
Total equity (KRW 100M) | — | 1,662.9 |
Returns & Leverage Ratios (KRW)
| Metric | FY2024 |
|---|---|
Proceeds from HQ disposal (KRW 100M) | 220 |
Returns & Leverage Ratios (%)
| Ratio | FY2025 |
|---|---|
ROE (%) | 4.4 |
Revenue by Region (KRW)
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Consolidated total (KRW 100M) | 2,337 | 2,711 | 3,069 |
Valuation Snapshot
| Metric | Value | Date / source |
|---|---|---|
Recent price | KRW 10,160 (Butler.works reading); KRW 10,550 (Stockhub, 8 Jul 2026) | — |
52-week range | KRW 7,280 – KRW 12,730 | Stockhub, Jul 2026 |
1-week / 1-month / 2-month / 6-month / 1-year return | −14.05% / −6.31% / +35.38% / +25.2% / +44.25% | MarketInOut, as of 20 Aug 2026 |
Notable move | Daily limit-up on Q1 2026 results day (14 May 2026) | Dailypharm |
Reference point | High-KRW-7,000s in Aug 2025 | Dealsite, 20 Aug 2025 |
Valuation Multiples
| Multiple | Ahn-Gook (Butler.works) | Ahn-Gook (MarketInOut, 20 Aug 2026) | Ahn-Gook (Stockhub, Jul 2026) | Peer reference |
|---|---|---|---|---|
P/E (x) | 6.12 | 7.54 | 8.36 | — |
P/B (x) | 0.74 | — | 0.70 | — |
EV/EBITDA (x) | — | 4.34 | — | — |
EV/EBIT (x) | — | 6.13 | — | — |
EV/Sales (x) | — | 0.40 | — | — |
Dividend yield (%) | 6.23 | — | — | Ranked #1 by FY2025 yield among 70 pharma/bio payers (~7%) |
Derived TTM P/E at KRW 10,160 (net income ≈ KRW 21.7bn, ≈ 11.4M shares outstanding ex-treasury) | ≈ 5.3 (derived) | — | — | — |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividend per share (KRW) | 220 | 220 | 220 | 440 | — |
Market dividend yield (%) | — | — | — | 6.6 | 7.0 |
Analyst Conclusions
Management guidance
There is no formal annual guidance. The stated ambition is KRW 500bn revenue and a UBIST top-10 ranking by 2030 (CEO Park In-cheol, Jan 2026). That implies roughly a 10% revenue CAGR from FY2025's KRW 306.9bn, a pace that H1 2026 (+25%) is comfortably exceeding.
Consensus expectations
There is no sell-side consensus. A simple run-rate gives FY2026 revenue of about KRW 380bn (H1 2026 of KRW 190.8bn × 2) before seasonality. Respiratory demand is typically stronger in H2/Q4, but the company has historically booked year-end charges. This is an analyst illustration, not guidance.
Bull case
-
Structural margin uplift. Mix shift to self-manufactured Fevarozet plus CMO volumes lifted the operating margin from 3.2% (FY2025) to 12.9% (H1 2026, derived). Sustaining even 10% on about KRW 350bn of revenue would roughly quadruple FY2025 operating profit.
-
Multiple growth vectors in place. The 1/10 mg Fevarozet strength, Widaplik's first-line triple combination, a dedicated liquid plant (2027) and H&B multichannel expansion each extend the runway beyond Synatura.
-
Deep-value entry with high yield. P/B of about 0.7, P/E of about 5–8x and a yield of about 6–7%. Treasury-share cancellation or further dividend increases could catalyse a re-rating.
Bear case
-
Owner legal tail risk. A conviction in the long-running rebate case could trigger reimbursement suspensions or price penalties on implicated products, and destabilise the co-CEO governance model.
-
Manufacturing compliance. The May–June 2026 tablet suspension hit the line that produces about 68% of parent revenue. A repeat violation would escalate penalties and could cost CMO customers.
-
Commoditisation. Pitavastatin/ezetimibe is crowding with low-dose generics, and price reform and PVA cuts could compress Fevarozet's economics just as the company commits about 29% of equity to capex.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| Q3 2026 quarterly report | Mid-Nov 2026 | Tests margin durability after the Q2 normalisation and the suspension period |
| FY2026 preliminary results and DPS decision | Feb–Mar 2027 | Dividend trajectory; Q4 charge pattern |
| Verdict in the Eo Jin rebate case and any administrative sanctions | Unscheduled | Largest single governance risk |
| Widaplik Korean clinical / MFDS milestones | 2026–2027 | New cardiovascular growth leg |
| Fevarozet 1/10 mg uptake and UBIST share vs Livalozet | Monthly UBIST data | Core franchise health |
| Drug-price reform implementation | 2026–2027 | Sector-wide earnings risk |
| Hyangnam expansion and liquid-plant progress | Through 2027–2028 | Capex discipline; capacity for growth |
| Treasury-share actions / Commercial Act reform | 2026–2027 | Potential re-rating catalyst |
| Identity of 5%+ holders behind 2026 large-holding filings | Ongoing | Shareholder-base changes |
| Mirae Asset fund deployments; MustBio–Celltrion progress | Ongoing | Option value |
Concluding analyst verdict
Ahn-Gook Pharmaceutical has completed an unglamorous but genuine turnaround. In 2020 it was a shrinking, owner-tainted generic house losing in-licensed brands. By 2026 it had a KRW 300bn-plus franchise whose growth comes from a product it developed, manufactures and supplies to most of its competitors. The 2026 earnings inflection, a 16% operating margin in Q1 and about 13% for H1, is the first evidence that scale and mix can lift a business that spent most of the past five years earning 2–5% margins. Fevarozet's leadership among followers, the toll-manufacturing position and a sensible pipeline of licensed and line-extension assets give the 2030 KRW 500bn target credibility. The current trajectory is already ahead of what that target requires.
The equity case, however, is not primarily operational. The market prices the stock below book and at mid-single-digit earnings multiples. That discount reflects three linked issues: governance (a controlling shareholder with a criminal conviction under appeal and a separate rebate trial pending for over six years), compliance (a recent GMP suspension on the core tablet line) and transparency (Korean-only filings, no investor communication, no sell-side coverage). The high dividend yield and unused 12.86% treasury block give patient holders a tangible return while those risks resolve.
On balance, Ahn-Gook screens as a fundamentally improving, governance-discounted value situation. The key swing factors are the rebate-case outcome and any associated reimbursement sanctions, proof that the post-suspension quality system holds, and whether the 2026 margin step-up survives the drug-price reform cycle. If all three resolve favourably, a re-rating toward book value and sector-average multiples is plausible. An adverse verdict with reimbursement penalties is the principal path to permanent impairment. Investors should obtain the DART filings directly for balance-sheet, cash-flow and related-party detail, which accessible secondary sources do not fully reproduce.
Sources referenced (by publisher): DART filings as transcribed by Butler.works, ETFshopping, MarketInOut, Stockhub, financialfilings.com and NICE/Catch.co.kr; Dailypharm (2019–2026); Medical Times (2018–2026); Dealsite (2019–2026); The Fact (2022–2024); Ajunews (Sep 2023); NewDaily (May 2025, May 2026); Medipharmhealth (Jul 2026); Digital Today (Oct 2025); Bizwatch (2019, Feb 2026); Dailian (Oct 2026); Opensurvey (2026); Daum/Hankyung (Apr 2026); Yahoo Finance, Morningstar, Simply Wall St, CB Insights, PatSnap, Fundable, Jobplanet (company profiles); Biospectator; Getcha; News Tomato.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Age / born |
|---|---|---|---|---|
Park In-cheol (박인철) | President & Representative Director (CEO) | Co-CEO from 2 Jan 2025; named sole representative in 2026 coverage | Head of Pharmaceutical Division; Head of Marketing; CEO of subsidiary Ahngook Newpharm. Credited with data-driven and digital marketing strategy | — |
Eo Jin (어진) | Vice Chairman; inside director; largest shareholder | CEO 1998–Mar 2022; inside director from Jan 2023; co-CEO from Nov 2024 (current representative status unconfirmed) | Second-generation owner | Born 1964 (Yahoo Finance) |
Won Deok-kwon (원덕권) | Former President & CEO | Sole CEO from Mar 2022; representative term expired 29 Mar 2025 | First professional CEO in company history | — |
Chang-Gyun Han (한창균) | Executive officer and director | — | — | Born 1963 (Yahoo Finance) |
Lee Seung-han (이승한) | Head of Legal | — | Testified at the National Assembly audit and apologised for past sales practices | — |
“—” = not publicly disclosed.
Governance Overview
| Item | Detail |
|---|---|
Independent (outside) directors | At least one outside director present at the 31 Oct 2025 board meeting (Digital Today); number not disclosed |
Audit function | Statutory auditor (감사) attended the 31 Oct 2025 meeting, indicating an auditor rather than an audit committee, consistent with KOSDAQ companies under KRW 2 trillion in assets |
Chair/CEO separation | Not disclosed. Historically the controlling family held both roles; the 2022–2024 professional-CEO period separated ownership from management |
Compliance systems | ISO 37001 and ISO 37301 certified since Dec 2021; compliance programme (CP) rules established; ESG management introduced (Dailypharm column) |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Mar 2022 | Eo Jin resigns as CEO on health grounds; Won Deok-kwon becomes sole CEO | Widely read as distancing the company from owner legal risk (The Fact) |
27 Jan 2023 | Eo Jin returns as inside director | Company said he would not serve as CEO or be involved in management (The Fact, Dec 2022) |
Nov 2024 | Eo Jin appointed co-CEO | Return to front-line management (Dealsite) |
2 Jan 2025 | Eo Jin / Park In-cheol co-representative system | Sales and marketing strengthening (Dailypharm) |
29 Mar 2025 | Won Deok-kwon's representative term expires | Dealsite (Dec 2024) linked his tenure to the outcome of Eo Jin's trial |
Feb 2025 | R&D and production organisation restructured | Dailypharm, 7 Feb 2025 |
Major Shareholders
| Holder | Stake (%) | Basis |
|---|---|---|
Eo Jin and related parties (largest-shareholder group) | 48.22 | 31 Dec 2025 (ETFshopping/DART); down from 49.75% at end-2021 |
Treasury shares | 12.86 | Butler.works |
Minority shareholders (8,420 holders) | 37.64 | 31 Dec 2025 (DART) |
Other / 5%+ holders | Not separately identified | Large-holding reports (주식등의대량보유상황보고서) were filed on 5 Jun, 30 Jun and 11 Sep 2026; filers not identified in sources reviewed |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Overlapping product(s) | Relative positioning | Source / basis |
|---|---|---|---|---|
Pitavastatin/ezetimibe | JW Pharmaceutical | Livalo, Livalozet (originator) | Market creator and leader in the combination; much larger company | Medical Times; Dealsite |
Pitavastatin/ezetimibe | Daewon Pharmaceutical | Tabarozet (KRW 18.2bn outpatient Rx vs Fevarozet KRW 29.2bn) | Second-largest follower; manufactured by Ahn-Gook | Medical Times, Mar 2026 |
Pitavastatin/ezetimibe | Boryung | Pitavastatin/ezetimibe combination (Ahn-Gook-made) | Partner-competitor | Dailypharm |
Pitavastatin/ezetimibe | Dongkwang Pharmaceutical | Combination (Ahn-Gook-made) | Partner-competitor | Dailypharm |
Pitavastatin/ezetimibe | Hanlim Pharm | Combination, including early 1/10 mg | Partner-competitor; low-dose first mover | Dailypharm, Apr 2026 |
Pitavastatin/ezetimibe low dose | Ilsung IS | First 1/10 mg generic (Jan 2026) | Low-dose pioneer | Dailypharm, Apr 2026 |
Pitavastatin/ezetimibe low dose | Daewoong Pharmaceutical | 1/10 mg generic | Large-company entrant | Dailypharm |
Pitavastatin/ezetimibe low dose | Ildong Pharmaceutical | 1/10 mg generic | Entrant | Dailypharm |
Rosuvastatin/ezetimibe & hypertension | Large domestic players (e.g., Hanmi, Chong Kun Dang, Yuhan) | Rosuvastatin/ezetimibe and ARB/CCB combinations | Larger scale and field forces | General industry knowledge; no figures verified here |
Respiratory (cough/sputum) | Domestic OTC/ETC respiratory brands (e.g., Hanmi's pelargonium syrup, Daewon's cough products) | Botanical and synthetic antitussives / expectorants | Synatura is a leading botanical prescription syrup; competitive shares not disclosed | General industry knowledge; no figures verified here |
Mid-tier generic peers | Kukje Pharmaceutical | Broad generics, ophthalmics | Smaller peer (FY2024 revenue KRW 156.5bn) | Dailypharm, Mar 2025 |
Mid-tier generic peers | Samjin Pharmaceutical | Cardiovascular, analgesics | Similar mid-tier peer; operating profit down 15% in FY2025 | Bizwatch, Feb 2026 |
Health functional foods | Chong Kun Dang Health, Daewoong, Ilyang, Dongkook, Donghwa and others in Daiso/Olive Young | HFF | Crowded: 22 pharma companies sell HFF at Daiso in 2026, up from 3, with about 160 items, up from about 30 | Dailian, 5 Oct 2026 |
Peer Comparison FY2024
| Metric | Ahn-Gook | JW Pharmaceutical | Kukje Pharmaceutical (FY2024) |
|---|---|---|---|
Revenue (KRW 100M) | 3,069 | 7,748 | 1,565 |
Revenue growth YoY (%) | 13.2 | 7.7 | — |
Operating income (KRW 100M) | 98 | 936 | 67 |
Operating margin (%) | 3.2 | 12.1 | 4.3 |
Net income (KRW 100M) | 73 | 617 | 52 |



